Stockreport

Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor [Yahoo! Finance]

Artelo Biosciences, Inc.  (ARTL) 
US:NASDAQ Investor Relations: artelobio.com/investors
PDF Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical- [Read more]